FDAnews/CenterWatch Announces -- Real World Evidence and Data: A Tufts Study of 30 Pharma Companies Webinar January 23, 2020HomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)FDAnews/CenterWatch Announces -- Real World Evidence and Data: A Tufts Study of 30 Pharma Companies Webinar January 23, 2020PR NewswireJanuary 9, 2020ReblogShareTweetShareUsing real world evidence in the next trial? Gain insights in support of development and post-approval safety studies.FALLS CHURCH, Va., Jan. 9, 2020 /PRNewswire-PRWeb/ -- Real World Evidence and Data: A Tufts Study of 30 Pharma Companies An FDAnews/CenterWatch Webinar Thursday, Jan. 23, 2020 • 1:30-3:00 p.m. EST https://www.centerwatch.com/rweanddataHow can one use real world evidence (RWE) and real world data (RWD) to generate evidence and identify gaps and challenges when conducting trials? The Tufts Center for the Study of Drug Development (CSDD) recent case studies can provide valuable insights.The CSDD investigated 30 biopharmaceutical companies use of RWD to generate evidence and showed the top measures for using RWE for return on investment, among other factors. It concluded that expanding the use of RWE in regulatory decisionmaking and increasing sponsors' use of RWD will fill critical gaps related to drug development and safety. The speakers will walk attendees through the study's important takeaways.Mary Jo Lamberti, PhD, a Tufts University professor and associate director of sponsored research at the CSDD, along with Francis Kendall, a 30-year pharmaceutical industry veteran and senior director at Cytel where he is an instrumental player in the company's Real World Analytics team, will discuss cases of what is being done with RWE and RWD: Types of technology used to access or collect RWD and evidence Significant challenges to using RWD Strategies and practices that impact return on investment or performance Key drivers for change and the adoption of RWE The potential of RWE and how it may be used across the clinical development pipeline A view on what will happen next in the RWE domain Understand the critical factors you need to consider in using RWE and gain insight into the current and planned uses of RWE to support development and post-approval safety studies.Interested in registering multiple sites? Call (888) 838-5578 in the U.S. or +1 (703) 538-7600 globally to learn about our special multisite discount.Webinar Details: Real World Evidence and Data: A Tufts Study of 30 Pharma Companies An FDAnews/CenterWatch Webinar Thursday, Jan. 23, 2020 • 1:30-3:00 p.m. EST https://www.centerwatch.com/rweanddataTuition: $287 per site Easy Ways to Register: Online: https://www.centerwatch.com/rweanddata By phone: 888-838-5578 or 703-538-7600About FDAnews: FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews' print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA's complex and ever-changing regulations.About CenterWatch: Founded in 1994, CenterWatch is a trusted source and global destination for clinical trials information for both professionals and patients. CenterWatch provides proprietary data and information analysis on clinical trials through a variety of newsletters, books, databases, and information services used by pharmaceutical and biotechnology companies, CROs, SMOs, and investigative sites involved in the management and conduct of clinical trials. As a pioneer in publishing clinical trials information, CenterWatch was the first Internet site to publish detailed information about active clinical trials that could be accessed by patients and their advocates. SOURCE CenterWatchReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextDoctor on Running Coronavirus Drug Trials: ‘You Go, Man’The Daily BeastGilead starts two late-stage studies to test drug for coronavirusReutersBiotech Stock Roundup: MRNA Surges, Pipeline Updates from INCY, HRTX & NGM BioZacksNovavax is working to advance a potential coronavirus vaccine. So are competitors.American City Business JournalsWhat's in the Cards for Zynerba (ZYNE) This Earnings Season?ZacksBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloomberg